Question 1

What is the catalog number for BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued?

Accepted Answer

The catalog number for BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued is 123990-ML750.

Question 2

What sizes are available for BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued?

Accepted Answer

BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued is available in the following size(s): 100 µL.

Question 3

Is BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued in stock?

Accepted Answer

BRCA2 (Breast Cancer Type 2 Susceptibility Protein, Fanconi Anemia Group D1 Protein, FACD, FANCD1) (MaxLight 750) discontinued

Selected Variant

123990-ML750

Size: 100 µL

Product Specifications

Clonality

Mab

Question 4

What is the shelf life of this product?

Accepted Answer

Shelf life and expiration dates vary by product and are shown on the product listing and label. Products used beyond their expiration date are not eligible for performance-related returns or refunds, so please check the lot number and expiry before use.

Question 5

What expression system was used for this recombinant protein?

Accepted Answer

The expression system, such as E. coli, HEK293, or insect cells, is listed on the datasheet under production details, which can affect post-translational modifications relevant to your application.

Question 6

Can I return this product if I ordered the wrong one?

Accepted Answer

As a consumer, you have a 14-day right of withdrawal from receipt under EU consumer protection law, submitted via our withdrawal/cancellation request form. Note this applies to unused, undamaged products, and doesn’t override the expiry/storage conditions on performance-based claims.